<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159299</url>
  </required_header>
  <id_info>
    <org_study_id>1511016854</org_study_id>
    <nct_id>NCT03159299</nct_id>
  </id_info>
  <brief_title>Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City</brief_title>
  <official_title>Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Iberoamericana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are:

        1. To translate an evidence-based diabetes self-management education (DSME) program, Yo
           Puedo!, to the cultural norms, expertise of providers, and systems of care in Seguro
           Popular clinics in Mexico. The program will be adapted through a collaborative team of
           diabetes experts in the US and Mexico, Seguro Popular clinic administrators, physicians,
           nurses and adults with type 2 diabetes (T2D) in Mexico City, Mexico. This will include
           development and testing of a theory-based mHealth (pictorial text-messaging) component.

        2. To evaluate the feasibility (process of implementation, fidelity of sessions,
           attendance, attrition), acceptability (interviews with nurse, CHW, participants) and
           preliminary efficacy of Yo Puedo!+mHealth in adults with T2D in Mexico City. A
           randomized, controlled pilot study design will be used in which 40 adults with T2D are
           randomized to the Yo Puedo! + mHealth or a wait-list control condition with the
           hypothesis that clinical [A1C, body mass index (BMI), blood pressure (BP)], T2D
           self-management, and self-efficacy outcomes will be greater in You Puedo!+mHealth
           participants compared to the wait-list control condition at 3 and 6 month follow-up. A
           secondary hypothesis that the Yo Puedo! + mHealth program is feasible and acceptable to
           adults with T2D and providers and that fidelity of the program will be maintained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This mixed-method design study will be accomplished in two phases with an interdisciplinary,
      bi-national collaboration between the Yale School of Nursing, the Yale School of Public
      Health, the Iberoamericana University in Mexico City, and up to 10 Seguro Popular clinics to
      evaluate the adapted DSME program for adults with T2D in Mexico City.

      Phase 1: While the Yo Puedo! program addresses some of the needs of Mexican adults with type
      2 diabetes - interactive health education for low health literacy, Spanish language materials
      and video novellas, and activities to enhance self-efficacy, the program was developed to
      address the needs of Latino immigrants in the U.S, who are from different Latin countries.
      The program needs to be adapted to Mexican adults with respect to personal beliefs about
      disease causation, cultural health practices, self-care practices of type 2 diabetes, and
      issues regarding access to care. This aim will be accomplished by using an interpretive and
      participatory method with a collaborative team of diabetes experts in the US and Mexico,
      Seguro Popular clinic administrators, physicians, and nurses, and adults with T2D in Mexico
      City, Mexico. In focus groups and interviews, the study team will explore how the cultural
      context, family, and health system shape beliefs and practices related to T2D. Access and
      familiarity with texting technology to identify potential barriers to using a text-messaging
      mHealth program will also be explored. These results will inform any modifications to the Yo
      Puedo! curriculum that may need to be made before Phase 2 can begin.

      Phase 2: A randomized, controlled pilot study design will be used in which 40 adults with T2D
      are randomized to the Yo Puedo + mHealth or wait-list control condition with the hypothesis
      that clinical (A1C, BMI, BP), T2D self-management, and self-efficacy outcomes will be greater
      in Yo Puedo + mHealth participants compared to the wait-list control condition at 3 and 6
      month follow-up. It is also hypothesized that the Yo Puedo + mHealth program is feasible and
      acceptable to adults with T2D and providers, and that fidelity of the program will be
      maintained. Those in the control group will be invited to participate in the program after
      completion of the 6-month data collection. Interviews will be conducted with the nurse,
      community health worker (CHW), participants, and select clinic personnel to identify
      barriers, facilitators, and acceptability of the program from multiple perspectives,
      recognizing the complexity of the health care system. Detailed notes on the process of
      implementation will be carefully recorded with the purpose of identifying successful and
      unsuccessful components of the program (positive and negative feedback loops in a complex
      system).

      Setting. The study will be conducted in up to 10 Seguro Popular clinics. These clinics are
      part of the Social Protection System in Health in Mexico. Individuals who obtain health care
      at these clinics are covered by public health insurance (Seguro Popular), and the services
      offered for T2D care include medical visits, referrals to specialists and nutritionist when
      needed, laboratory testing, and free medicines. The medical visits include medication
      prescription, blood pressure management, lipid monitoring, and eye/foot care. Laboratory
      analyses vary from patient to patient but generally includes 3 annual tests of A1C, although
      other glucose, urine, and lipids tests are also available. Patients with complications are
      referred to specialized health centers. Evidence suggests that the impact of the Seguro
      Popular in adults with T2D has been positive.

      Interventions. All participants will receive standard T2D care at a Seguro Popular clinic as
      described above. The wait-list control condition group will receive a handout on T2D
      self-management and the opportunity to participate in the Yo Puedo! + mHealth program at the
      completion of 6-month data collection. The Yo Puedo! + mHealth DSME program includes: a) an
      initial consultation with the nurse to collaboratively determine goals; b) five interactive
      group-based sessions led by the CHW on T2D self-management that is culturally relevant and at
      a low health literacy level (Yo Puedo! protocol adapted for Mexican context; c) behavioral
      support to collaboratively problem-solve barriers to change; and d) empowerment-based
      strategies to facilitate provider-patient communication. The Yo Puedo! program will be
      supplemented by 2-way text-messaging capability provided by a web-based platform with privacy
      and security rules, which allows for automated and personalized messages and a database to
      store all messages. Automated daily text messages will include messages to promote
      understanding of T2D self-management, self-efficacy, and adherence to self-management goals.
      The in-person component will be 6 weeks; daily text messaging will be for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1C From Baseline</measure>
    <time_frame>Baseline, 3, 6 months</time_frame>
    <description>The change in A1C from baseline to 6 months is the result of the Generalized Linear Mixed Models (GLMM) with an intent-to-treat analysis that was used. HbA1c was measured from finger stick blood sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Systolic and Diastolic Blood Pressure From Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Systolic and Diastolic Blood Pressure From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Baseline</time_frame>
    <description>A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI) From Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI) From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Self-management</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Self-management From Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Self-management From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Intake</measure>
    <time_frame>Baseline</time_frame>
    <description>Dietary intake will be evaluated by a two-day diet history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dietary Intake From Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Dietary intake will be evaluated by a two-day diet history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dietary Intake From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Dietary intake will be evaluated by a two-day diet history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Activity From Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Activity From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Self-Efficacy</measure>
    <time_frame>Baseline</time_frame>
    <description>Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Self-Efficacy From Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Self-Efficacy From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Satisfaction With Program</measure>
    <time_frame>6 months</time_frame>
    <description>This measure will be used to evaluate the acceptability of the Yo Puedo program. Participants will be given a short survey and interview about their experience and satisfaction with the program.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Recruitment</measure>
    <time_frame>through study completion, about 1 year</time_frame>
    <description>Rates of recruitment will be collected by researchers to evaluate feasibility.</description>
  </other_outcome>
  <other_outcome>
    <measure>Attrition</measure>
    <time_frame>through study completion, about 1 year</time_frame>
    <description>This will be collected by researchers to evaluate feasibility. The number of participants who do not complete the study interventions and the reasons why will be recorded by study personnel.</description>
  </other_outcome>
  <other_outcome>
    <measure>Protocol Implementation</measure>
    <time_frame>through study completion, about 1 year</time_frame>
    <description>This will be collected by researchers to evaluate feasibility. The CHWs will complete a Protocol Implementation Form after each session that documents attendance, length of the session, content of session, protocol implementation, and any deviation from protocol implementation</description>
  </other_outcome>
  <other_outcome>
    <measure>Fidelity of Yo Puedo Sessions</measure>
    <time_frame>through study completion, about 1 year</time_frame>
    <description>This will be collected by researchers to evaluate feasibility. A study Co-Investigator will observe 10% of sessions to evaluate fidelity of Yo Puedo sessions.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Yo Puedo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive the modified Yo Puedo + mHealth program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-list Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Yo Puedo + mHealth</intervention_name>
    <description>This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.</description>
    <arm_group_label>Yo Puedo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase 1:

          -  For provider interviews/focus groups: administrator or health care provider at Seguro
             Popular clinic with at least 3 months experience.

          -  For adult interviews/focus groups: 21-65 years of age and have had T2D for at least
             one year

        Phase 2:

          -  Age 21-65 years; receiving care for T2D at a Seguro Popular clinic; diagnosed with T2D
             with A1C &gt;8.0% and duration â‰¤ 5 years; medically stable and safe to exercise; and have
             a cell phone (MMS text-messaging will be provided).

        Exclusion Criteria:

        Phase 2:

          -  Cognitive impairment, severe untreated clinical depression in the past 6 months, major
             cardiac event in past 12 months, uncontrolled blood pressure, resting tachycardia,
             renal failure, severe peripheral neuropathy, treatment of T2D with insulin, and
             participation in focus groups or interviews.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Whittemore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Nursing</name>
      <address>
        <city>Orange</city>
        <state>Connecticut</state>
        <zip>06477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <results_first_submitted>March 9, 2020</results_first_submitted>
  <results_first_submitted_qc>April 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2020</results_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mHealth</keyword>
  <keyword>Hispanic/Latinos</keyword>
  <keyword>Diabetes Self-Management Education</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>April 2020 - December 2020</ipd_time_frame>
    <ipd_access_criteria>Contact the Principal Investigator</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03159299/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Yo Puedo</title>
          <description>This group will receive the modified Yo Puedo + mHealth program.
Yo Puedo + mHealth: This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Wait-list Control</title>
          <description>This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Yo Puedo</title>
          <description>This group will receive the modified Yo Puedo + mHealth program.
Yo Puedo + mHealth: This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Wait-list Control</title>
          <description>This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="9.2"/>
                    <measurement group_id="B2" value="56.8" spread="8.3"/>
                    <measurement group_id="B3" value="55.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin A1C From Baseline</title>
        <description>The change in A1C from baseline to 6 months is the result of the Generalized Linear Mixed Models (GLMM) with an intent-to-treat analysis that was used. HbA1c was measured from finger stick blood sample.</description>
        <time_frame>Baseline, 3, 6 months</time_frame>
        <population>Intention to treat analysis included all observations for all relevant time points used in the calculation.</population>
        <group_list>
          <group group_id="O1">
            <title>Yo Puedo</title>
            <description>This group will receive the modified Yo Puedo + mHealth program.
Yo Puedo + mHealth: This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Wait-list Control</title>
            <description>This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1C From Baseline</title>
          <description>The change in A1C from baseline to 6 months is the result of the Generalized Linear Mixed Models (GLMM) with an intent-to-treat analysis that was used. HbA1c was measured from finger stick blood sample.</description>
          <population>Intention to treat analysis included all observations for all relevant time points used in the calculation.</population>
          <units>percentage HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.30"/>
                    <measurement group_id="O2" value="-0.97" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.32" spread="1.44"/>
                    <measurement group_id="O2" value="9.09" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.85" spread="1.40"/>
                    <measurement group_id="O2" value="8.76" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.56" spread="1.50"/>
                    <measurement group_id="O2" value="8.05" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.15</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Systolic and Diastolic Blood Pressure</title>
        <description>Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Systolic and Diastolic Blood Pressure From Baseline</title>
        <description>Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Systolic and Diastolic Blood Pressure From Baseline</title>
        <description>Systolic and diastolic BP will be measured according to practice standards. Two readings separated by 1 minute will be averaged</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index (BMI) From Baseline</title>
        <description>A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2.</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index (BMI) From Baseline</title>
        <description>A calibrated electronic scale will be used to record weight and a wall-based stadiometer will be used to record height. Weight and height will be combined to report BMI in kg/m^2.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetes Self-management</title>
        <description>Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diabetes Self-management From Baseline</title>
        <description>Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diabetes Self-management From Baseline</title>
        <description>Measured by the Summary of Diabetes Self-Care Activities questionnaire, a multi-dimensional12-item scale with items on general diet, specific diet, monitoring blood glucose, foot care, and smoking</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dietary Intake</title>
        <description>Dietary intake will be evaluated by a two-day diet history</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dietary Intake From Baseline</title>
        <description>Dietary intake will be evaluated by a two-day diet history</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dietary Intake From Baseline</title>
        <description>Dietary intake will be evaluated by a two-day diet history</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Activity</title>
        <description>Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Activity From Baseline</title>
        <description>Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer.</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Activity From Baseline</title>
        <description>Physical activity will be measured by accelerometer, using the Actigraph Actigraphy, a 3-axial accelerometer.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetes Self-Efficacy</title>
        <description>Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diabetes Self-Efficacy From Baseline</title>
        <description>Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy.</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diabetes Self-Efficacy From Baseline</title>
        <description>Self-efficacy will be measured by the Stanford Diabetes Self-Efficacy Scale, an 8-item scale specific to T2D self-management self-efficacy.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Satisfaction With Program</title>
        <description>This measure will be used to evaluate the acceptability of the Yo Puedo program. Participants will be given a short survey and interview about their experience and satisfaction with the program.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Recruitment</title>
        <description>Rates of recruitment will be collected by researchers to evaluate feasibility.</description>
        <time_frame>through study completion, about 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Attrition</title>
        <description>This will be collected by researchers to evaluate feasibility. The number of participants who do not complete the study interventions and the reasons why will be recorded by study personnel.</description>
        <time_frame>through study completion, about 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Protocol Implementation</title>
        <description>This will be collected by researchers to evaluate feasibility. The CHWs will complete a Protocol Implementation Form after each session that documents attendance, length of the session, content of session, protocol implementation, and any deviation from protocol implementation</description>
        <time_frame>through study completion, about 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fidelity of Yo Puedo Sessions</title>
        <description>This will be collected by researchers to evaluate feasibility. A study Co-Investigator will observe 10% of sessions to evaluate fidelity of Yo Puedo sessions.</description>
        <time_frame>through study completion, about 1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately one year</time_frame>
      <desc>Data were collected on episodes of hypoglycemia or hyperglycemia at data collection times (3 and 6 months). There were 10 minor adverse events of hyperglycemia or hypoglycemia possibly or unrelated to study. There was one major adverse event of hypoglycemia requiring emergency room treatment of participant in the control group, unlikely related to the study. All treatment-related and non-treatment related adverse events are being reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Yo Puedo</title>
          <description>This group will receive the modified Yo Puedo + mHealth program.
Yo Puedo + mHealth: This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Wait-list Control</title>
          <description>This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>hypoglycemia</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Severe hypoglycemia requiring emergency room treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>hypoglycemia</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemic</sub_title>
                <description>Minor hypoglycemia resolved without medical intervention other than food for hypoglycemia.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title vocab="hyperglycemia">hyperglycemia</sub_title>
                <description>Minor hyperglycemia resolved without treatment</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robin Whittemore, PhD</name_or_title>
      <organization>Yale School of Nursing</organization>
      <phone>203-737-2351</phone>
      <email>robin.whittemore@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

